Psychobiotics Research Targets Depression via Gut-Brain Axis
SkimNews Take
If microbial interventions produce measurable cognitive change, the gut-brain axis shifts from a correlational observation to a causal lever, reframing psychiatric drug development around ecosystem-level targets rather than neurotransmitter chemistry.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Microbial neuroscience has transformed from a ridiculed field—where Professor Phil Burnet of the University of Oxford recalls 'sniggering at the back of the seminar room' 15 years ago—into a rapidly accelerating area of study over the past decade.
- The gut microbiome contains roughly 100 trillion microbial cells from as many as 5,000 species, and communicates with the brain via the vagus nerve and the enteric nervous system, which holds an estimated 500 million neurons—more than double the spinal cord.
- King's College London and ADM published a study in JAMA Psychiatry in 2023 exploring the effects of a probiotic in people with major depression, part of a growing wave of clinical trials testing gut interventions for depression, anxiety, bipolar disorder, OCD, ADHD, stress, and early Alzheimer's research.
- Postbiotics—heat-treated or otherwise inactivated microbes—can still produce biological effects; ADM researchers found that heat-treated bacteria yielded similar results to live strains in IBS patients, and postbiotic effects can appear within an hour but wear off when administration stops.
- ADM also ran a 72-person trial testing whether postbiotics can reduce symptoms of allergic rhinitis, and postbiotics' stability advantage means they could be added to foods or drinks rather than swallowed as pills.
- Researchers including Dr. Richard Day and Dr. Malwina Naghibi of ADM emphasize that larger, longer studies are still needed to confirm how robust any mental health impacts truly are, calling microbial neuroscience 'a field in its infancy.'
Why it matters: If larger trials confirm early signals, the roughly 100 trillion microbes in the human gut could become a legitimate therapeutic target for depression and anxiety—conditions that millions of patients struggle to treat with existing drugs. For ADM, which is actively researching and marketing psychobiotics across IBS, depression, and allergic rhinitis, this represents both a commercial pipeline and a potential paradigm shift in how mental health is treated.
